Ramipril versus placebo in kidney transplant patients with proteinuria: A multicentre, double-blind, randomised controlled trial

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 4, 2016, Pages 318-326

  Knoll, Greg A ^a,b   Fergusson, Dean ^a,b   Chassé, Michaël ^b   Hebert, Paul ^c   Wells, George ^b   Tibbles, Lee Anne ^d   Treleaven, Darin ^e   Holland, David ^f   White, Christine ^f   Muirhead, Norman ^g   Cantarovich, Marcelo ^h   Paquet, Michel ^c   Kiberd, Bryce ⁱ   Gourishankar, Sita ^j   Shapiro, Jean ^k   Prasad, Ramesh ^l   Cole, Edward ^m   Pilmore, Helen ⁿ   Cronin, Valerie ^b   Hogan, Debora ^b   Ramsay, Tim ^b   Gill, John ^o   more..

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

^j UNIVERSITY OF ALBERTA   (Canada)

^k VANCOUVER GENERAL HOSPITAL   (Canada)

^l ST MICHAEL'S HOSPITAL   (Canada)

^m UNIVERSITY HEALTH NETWORK   (Canada)

ⁿ UNIVERSITY OF AUCKLAND   (New Zealand)

^o ST PAUL S HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RAMIPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE; CANADA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HUMAN; HYPERKALEMIA; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEW ZEALAND; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; REVASCULARIZATION; SIDE EFFECT; ADVERSE EFFECTS; CLINICAL TRIAL; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROTEINURIA; RAMIPRIL; RISK FACTORS;

EID: 84951094623     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00368-X     Document Type: Article

References (35)

1. Karthikeyan V, Karpinski J, Nair RC, Knoll G The burden of chronic kidney disease in renal transplant recipients. Am J Transplant 2004, 4:262-269.
2. Knoll G Proteinuria in kidney transplant recipients: prevalence, prognosis and evidence-based management. Am J Kidney Dis 2009, 54:1131-1144.
3. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012, 2:337-414. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group.
4. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer W, Curhan G, Oberbauer R Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006, 17:889-899.
5. Opelz G, Zeier M, Laux G, Morath C, Döhler B No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant Study Report. J Am Soc Nephrol 2006, 17:3257-3262.
6. Hiremath S, Fergusson D, Doucette S, Mulay A, Knoll GA Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007, 7:2350-2360.
7. Cross NB, Webster A, Masson P, O'Connell P, Craig JC Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009, 88:7-18.
8. Jennings DL, Taber DJ Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation. Ann Pharmacother 2008, 42:116-120.
9. Knoll G, Cantarovitch M, Cole E, et al. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation: study design. Nephrol Dial Transplant 2008, 23:354-358.
10. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43:S1-S290. Kidney Disease Outcomes Quality Initiative (K/DOQI).
11. K/DOQI clinical practice guidelines for managing dyslipidemias in kidney transplant patients. Am J Transplant 2004, 4:13-53. Kidney Disease Outcomes Quality Initiative (K/DOQI).
12. White C, Akbari A, Doucette S, et al. Estimating GFR using serum beta trace protein: accuracy and validation in kidney transplant and pediatric populations. Kidney Int 2009, 76:784-789.
13. Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 2010, 25:967-976.
14. Ibrahim HN, Jackson S, Connaire J, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol 2013, 24:320-327.
15. Paoletti E, Cassottana P, Amidone M, Gherzi M, Rolla D, Cannella G ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. Am J Kidney Dis 2007, 50:133-142.
16. Paoletti E, Bellino D, Marsano L, Cassottana P, Rolla D, Ratto E Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial. Transplantation 2013, 95:889-895.
17. Rao A, Pitcher D, Farrington K UK Renal Registry 16th Annual Report: Chapter 11, Blood Pressure Profile of Prevalent Patients receiving Renal Replacement Therapy in 2012: National and Centre-specific Analyses. Nephron Clin Pract 2013, 125:209-218.
18. Lewis EJ, Hunsicker LG, Bain RP The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462. Rohde RD for the Collaborative Study Group.
19. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869. for the RENAAL Study Investigators.
20. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860. for the Collaborative Study Group.
21. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354:359-364.
22. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334:939-945.
23. Kidney disease: improving global outcomes (KDIGO) clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012, 2:337-414. Kidney Disease: Improving Global Outcomes Group.
24. Weir MR, Burgess E, Cooper JE, et al. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol 2015, published online Feb 4. 10.1681/ASN.2014080834.
25. Cravedi P, Perico N, Remuzzi G Non-immune interventions to protect kidney allografts in the long term. Kidney Int Suppl 2010, 78:S71-S75.
26. Mariat C Early use of renin-angiotensin-aldosterone system inhibitors after renal transplantation. Nat Clin Pract Nephrol 2008, 4:306-307.
27. Morath C, Schmied B, Mehrabi A, et al. Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation. Clin Transplant 2009, 23:33-36.
28. Wadei HM, Textor SC Hypertension in the kidney transplant recipient. Transplant Rev (Orlando) 2010, 24:105-120.
29. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719-2728.
30. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153. The Heart Outcomes Prevention Evaluation Study Investigators.
31. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863. The GISEN Group.
32. Jones H, Talwar M, Nogueira JM, et al. Anemia after kidney transplantation; its prevalence, risk factors, and independent association with graft and patient survival: a time-varying analysis. Transplantation 2012, 93:923-928.
33. Garrigue V, Szwarc I, Giral M, et al. Influence of anemia on patient and graft survival after renal transplantation: results from the French DIVAT cohort. Transplantation 2014, 97:168-175.
34. Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2015, 66:S1-306.
35. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, 9:S1-S157. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group.